Julia v. Tresckow

Department for Hematology, Oncology and Palliative Care, Catholic Clinic Bochum, Ruhr Univer-sity Bochum, Germany, Germany

N/A

Poster(s):

• 1442 - NGS-based MRD assessment refines prognostication after venetoclax-based first-line combinations for chronic lymphocytic leukemia: A prospective analysis of the phase 3 GAIA/CLL13 trial

• 1515 - Re-Treatment with Venetoclax-Obinutuzumab after time-limited, MRD-guided Venetoclax-Obinutuzumab: final analysis of 7 patients with chronic lymphatic leukemia (CLL) treated in the CLL2-BAG trial of the GCLLSG.